Business
VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple
About this update from Vyne Therapeutics Inc.
[{"type":"text","content":"Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to host KOL webinar on InhiBETTM BET inhibitor platform on May 17th BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the quarter ended March 31, 2022 and provided a business update. “VYNE made significant progress in the first quarter of 2022 with our pipeline of novel programs for immuno-inflammatory conditions,” said David Domzalski, Chief Executive Officer of VYNE. “We reported positive Phase 1b safety and efficacy data for FMX114 in mild-to-moderate atopic dermatitis, released promising preclinical data for our locally-administered pan-BD BET inhibitor, VYN201, and completed the divestiture of our topical minocycline franchise.” “Looking ahead, we plan to report Phase 2a safety and efficacy results for FMX114 by the end of the second quarter. We are pleased with our toxicology and scale-up activities for VYN201 and remain on schedule to initiate our first in-human clinical study for our lead indication in the second half of this year. In addition, we continue to work with our partner In4Derm on final candidate selection for VYN202,” continued Mr. Domzalski. “We look forward to providing updates to investors throughout the year as we advance our pipeline of proprietary immuno-inflammatory therapeutics.” Pipeline Update FMX114 - FMX114 is VYNE’s proprietary investigational combination gel formulation of tofacitinib and fingolimod that is designed to address both the source and cause of inflammation in mild-to-moderate atopic dermatitis (“AD”). FMX114 has the potential to be the first topical combination product for the treatment of AD. FMX114 is currently being evaluated in a Phase 2a study with topline results expected by the end of the second quarter. VYNE previously conducted a Phase 1b study (n=4) to evaluate the preliminary clinical safety, dermal tolerance and pharmacokinetics of FMX114 and vehicle when topically applied to individual qualifying AD lesions for 2 weeks. Efficacy was a...